Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL


Share

Program Content

Activities

  • Managing CLL and MCL With BTKi
    Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 13, 2023

  • BTKi in CLL/SLL and MCL
    BTK Inhibitors in CLL/SLL and MCL: The Latest Guidance and Evidence for the Clinic
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2023

Faculty

cover img faculity

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center 9500 Euclid Avenue CA-6
Cleveland, Ohio

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC